Evidence map›Paper›PMID 26066626›Full record

ArticleAJNR. American journal of neuroradiology2015

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

M A Prah, S M Stufflebeam, E S Paulson, J Kalpathy-Cramer, E R Gerstner, T T Batchelor, D P Barboriak, B R Rosen, K M Schmainda

Abstract read
In one paragraph

Article in AJNR. American journal of neuroradiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Advanced MR Techniques for Preoperative Glioma Characterization: Part 1.Journal of magnetic resonance imaging : JMRI · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M A PrahFrom the Departments of Radiology (M.A.P., K.M.S., E.S.P.).
S M StufflebeamDepartment of Radiology (S.M.S., J.K.-C., E.R.G., T.T.B., B.R.R.), Massachusetts General Hospital, Boston, Massachusetts.
E S PaulsonFrom the Departments of Radiology (M.A.P., K.M.S., E.S.P.) Radiation Oncology (E.S.P.), Medical College of Wisconsin, Milwaukee, Wisconsin.
J Kalpathy-CramerDepartment of Radiology (S.M.S., J.K.-C., E.R.G., T.T.B., B.R.R.), Massachusetts General Hospital, Boston, Massachusetts.
E R GerstnerDepartment of Radiology (S.M.S., J.K.-C., E.R.G., T.T.B., B.R.R.), Massachusetts General Hospital, Boston, Massachusetts.
T T BatchelorDepartment of Radiology (S.M.S., J.K.-C., E.R.G., T.T.B., B.R.R.), Massachusetts General Hospital, Boston, Massachusetts.
D P BarboriakDepartment of Radiology (D.P.B.), Duke University Medical Center, Durham, North Carolina.
B R RosenDepartment of Radiology (S.M.S., J.K.-C., E.R.G., T.T.B., B.R.R.), Massachusetts General Hospital, Boston, Massachusetts.
K M SchmaindaFrom the Departments of Radiology (M.A.P., K.M.S., E.S.P.) kathleen@mcw.edu.

Funding

AZD2171 and chemoradiation for newly diagnosed glioblastomaR01CA129371 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2017
$6.2M
MRI CONTRAST AGENT METHODS TO ASSESS TUMOR ANGIOGENESISR01CA082500 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI SCHMAINDA, KATHLEEN MARIE · 2000 to 2016
$5.0M
Quantitative (Perfusion and Diffusion) MRI Biomarkers to Measure Glioma ResponseU01CA176110 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI SCHMAINDA, KATHLEEN MARIE · 2014 to 2023
$4.9M
Quantitative MRI of Glioblastoma ResponseU01CA154601 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KALPATHY-CRAMER, JAYASHREE · 2011 to 2016
$3.4M
Functional Connectivity of Intrinsic Brain Activity for Presurgical MappingR01NS069696 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI STUFFLEBEAM, STEVEN · 2011 to 2015
$2.9M
Clinical and Molecular Studies of Novel Therapeutics in Malignant Brain TumorsK24CA125440 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2016
$1.9M
Toward Multi-Center MR Brain PerfusionR01NS060918 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMAINDA, KATHLEEN MARIE, STUFFLEBEAM, STEVEN · 2010 to 2014
$1.8M
NCI NIH HHS 2 K24 CA125440-06NCI NIH HHS 2 R01 CA129371-06NCI NIH HHS 5U01CA154601NCI NIH HHS K24 CA125440NCI NIH HHS R01 CA082500NCI NIH HHS R01 CA129371NCI NIH HHS U01 CA154601NCI NIH HHS U01 CA176110NINDS NIH HHS R01 NS060918NINDS NIH HHS R01 NS069696
6 · The paper itself

Abstract

background and purposeFor more widespread clinical use advanced imaging methods such as relative cerebral blood volume must be both accurate and repeatable. The aim of this study was to determine the repeatability of relative CBV measurements in newly diagnosed glioblastoma multiforme by using several of the most commonly published estimation techniques. MATERIALS AND

methodsThe relative CBV estimates were calculated from dynamic susceptibility contrast MR imaging in double-baseline examinations for 33 patients with treatment-naïve and pathologically proved glioblastoma multiforme (men = 20; mean age = 55 years). Normalized and standardized relative CBV were calculated by using 6 common postprocessing methods. The repeatability of both normalized and standardized relative CBV, in both tumor and contralateral brain, was examined for each method with metrics of repeatability, including the repeatability coefficient and within-subject coefficient of variation. The minimum sample size required to detect a parameter change of 10% or 20% was also determined for both normalized relative CBV and standardized relative CBV for each estimation method.

resultsWhen ordered by the repeatability coefficient, methods using postprocessing leakage correction and ΔR2*(t) techniques offered superior repeatability. Across processing techniques, the standardized relative CBV repeatability in normal-appearing brain was comparable with that in tumor (P = .31), yet inferior in tumor for normalized relative CBV (P = .03). On the basis of the within-subject coefficient of variation, tumor standardized relative CBV estimates were less variable (13%-20%) than normalized relative CBV estimates (24%-67%). The minimum number of participants needed to detect a change of 10% or 20% is 118-643 or 30-161 for normalized relative CBV and 109-215 or 28-54 for standardized relative CBV.

conclusionsThe ΔR2* estimation methods that incorporate leakage correction offer the best repeatability for relative CBV, with standardized relative CBV being less variable and requiring fewer participants to detect a change compared with normalized relative CBV.

Indexed as

AdultAgedBlood Volume DeterminationBrain NeoplasmsFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedReference Standards

Identifiers

PMID26066626
PMCPMC4567906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.